BioAtla, Inc

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioAtla reports positive trial results and financial stability in Q4

BioAtla's Q4 2022 earnings call highlighted positive trial results, strong financial position, and progress in clinical development efforts
While facing challenges such as increased R&D expenses and enrollment hurdles, the company remains focused on innovation and patient safety
Opportunities lie in leveraging dosing regimens for enhanced efficacy, responding to patient needs, and updating stakeholders on future advancements

BioAtla reports positive clinical responses and solid financial position

BioAtla showcased strong clinical progress in Phase 2 trials, with positive responses in various cancer indications. Despite financial losses, the company maintains a solid cash position. Challenges lie in optimizing dosing and balancing characteristics in combination therapies, while opportunities exist in furthering combination therapy research and FDA interactions.

BioAtla reports progress in novel cancer therapies and financial stability

BioAtla is making significant strides in developing novel therapies for solid tumor types with high unmet medical needs.
The company's financial position is stable with plans to fund operations into 2025 and explore strategic partnerships.
Challenges include managing R&D expenses, rolling out liquid biopsy to other indications, and optimizing combination therapy approaches.
Opportunities lie in potential corporate development, strategic partnerships, and expanding treatment options with promising combination therapies.

BioAtla reports positive clinical trial results and strong financial position

BioAtla showcased promising clinical trial results for BA3011 and BA3021, with a focus on delivering innovative therapies for cancer treatment. Despite increased expenses and a net loss in Q3 2023, the company maintains a strong financial position and aims to maximize shareholder value through strategic collaborations and advancements in its pipeline.

BioAtla reports strong clinical progress and financial review in Q4

BioAtla's Q4 2023 earnings call highlighted substantial progress in clinical programs, financial performance, and strategic plans for future growth.
The company's focus on advancing CAB programs, innovative therapies, and collaborations underscores its commitment to driving clinical and commercial success.
While facing challenges in regulatory processes and trial execution, BioAtla remains well-positioned to leverage opportunities for market expansion and therapeutic innovation.

BioAtla reports positive clinical data and financial progress in Q1 2024 earnings call

BioAtla's Q1 2024 Earnings Call showcased positive clinical data, financial improvements, and strategic advancements in its pipeline.
The company's focus on safety, enthusiasm from leadership, and plans for future trials indicate a promising outlook for its drug development programs.
While facing challenges in differentiation, safety management, and financial sustainability, BioAtla remains poised to capitalize on market opportunities and collaborations.

BioAtla reports robust Q3 earnings with promising oncology pipeline progress

BioAtla's Q3 2024 earnings call highlighted strong financial performance and significant advancements in their oncology pipeline, supported by positive clinical data and regulatory feedback.
The company's focus on key compounds like ozuriftamab vedotin and evalstotug in various cancer types positions them well for future growth and potential commercial success.
While challenges in clinical trial execution and regulatory complexities exist, BioAtla has opportunities to capitalize on FDA support, expand indications, and drive innovation in precision oncology.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed

Eiger BioPharmaceuticals

Gracell Biotechnologies

Immuneering Corp

Nkarta, Inc.

Instil Bio

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

7 Cheap But Risky Biotech Stocks

SAN DIEGO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones. Company updates and 2023 milestones will be presented in a fireside chat at 41st Annual J.P. Morgan Healthcare Conference, January 10, 2023.

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Viatris

Directors Neil Dimick and Ian Read Retire PITTSBURGH , Dec. 29, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W.

Viatris Announces Appointments of Scott A. Smith and Elisha W.

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat and one-on-one investor meetings at the 41st Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 9-12, 2023.

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?

BioAtla, Inc. (NASDAQ:BCAB ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations Jay Short - Chairman, Chief Executive Officer and Co-Founder Scott Smith - President Philippe Martin - Chief, Clinical Development and Operations Sheri Lydick - Senior Vice President, Commercial Strategy Richard Waldron - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Kelly Shi - Jefferies Tony Butler - ROTH Capital Arthur He - H.C. Wainwright Reni Benjamin - JMP Securities Operator Good day and welcome to the BioAtla Third Quarter 2022 Earnings Conference Call – pardon me, BioAtla.

BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 shares of its common stock at a price of $6.67 per share in an underwritten offering. The gross proceeds of the offering to BioAtla before deducting estimated underwriting discount and commissions and estimated offering expenses are expected to be approximately $65 million. The offering is expected to close on or about November 8, 2022, subject to the satisfaction of customary closing conditions.

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the third quarter ended September 30, 2022, and provided clinical program updates for both mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) addressing multiple tumor types as well as updates on CAB-CTLA-4 (BA3071) and CAB-EpCAMxCAB-CD3 bispecific T-cell engager (TCE) (BA3182).

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 3, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide business highlights.

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

Shares of conditionally active biologics concern BioAtla, Inc. are beginning to rebound from a 97% plunge as encouraging data from two candidates has sparked the turnaround. BioAtla leverages its expertise of the tumor microenvironment to develop highly selective and reversible biologics, with applications across the entire antibody-based biologic spectrum.

BioAtla: Back From The Dead

Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 Undifferentiated Pleomorphic Sarcoma ("UPS") and osteosarcoma will advance to Phase 2, part 2 enrollment, which is anticipated to begin 4Q'22 SAN DIEGO and SHANGHAI , Sept. 12, 2022 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced interim topline data update from the HTBA3011 in NSCLC and certain sarcomas.

Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

BioAlta shares have lost nearly three-quarters of their value over the past 3 years. Management has not done a good job of keeping lines of communication open and has a history of postponing clinical data timelines.

BioAtla: Promising Signal In NSCLC, But Concerns Remain

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - President Philippe Martin - Chief of Clinical Development and Operations Sheri Lydick - SVP, Commercial Strategy Richard Waldron - CFO Conference Call Participants Kelly Shi - Jefferies Arthur He - H.C. Wainwright Tony Butler - ROTH Capital Operator Hello and welcome to the BioAtla Second Quarter 2022 Earnings Call.

BioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results - Earnings Call Transcript

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the second quarter ended June 30, 2022, and provided an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in NSCLC as well as an operational update on its ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071) addressing multiple tumor types.

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference, to be held in New York, NY Monday, August 8, 2022.

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, August 9, 2022 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide business highlights.

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder, and Scott Smith, President, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY June 8-10, 2022.

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - President Philippe Martin - Chief of Clinical Development and Operations Sheri Lydick - Senior Vice President, Commercial Strategy Richard Waldron - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Tiago Fauth - Credit Suisse Kelly Shi - Jefferies Kaveri Pohlman - BTIG Tony Butler - ROTH Capital Arthur He - H.C. Wainwright Operator Good day, and thank you for standing by.

BioAtla, Inc. (BCAB) CEO Jay Short on Q1 2022 Results - Earnings Call Transcript

– Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –

BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071).

BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

SAN DIEGO, March 1, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announces its financial results for the fourth quarter and full year December 31, 2021, and provides an update on product pipeline developments. "BioAtla made significant progress in 2021 by advancing the potentially registration-enabling Phase 2 clinical trials for our two lead CAB product candidates as well as our other preclinical and pipeline programs.

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

Bristol-Myers

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo® (nivolumab).  Under the terms of the agreement, BioAtla and Bristol Myers Squibb will collaborate on clinical trials of separate combination therapies using two of BioAtla's Conditionally Active Biologic Antibody Drug Conjugates, BA3011 and BA3021, each in combination with Opdvio.

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

News for BioAtla, Inc Stock (BCAB)